Johnson & Johnson Reports Strong Q3 2023 Results with Stelara Generating $8.1B and Carvykti Revenue at $341M Year-to-Date

Oct 18, 2023 07:47 CST Updated 07:47

Johnson & Johnson

Healthcare Product Manufacturers, Health Service Providers

On October 17, Johnson & Johnson released its 2023 Q3 financial report. The total revenue for the first three quarters was $63.764 billion, representing a year-on-year increase of 6.2%. The Q3 revenue reached $21.351 billion, marking a year-on-year growth of 6.8%. The company invested $10.605 billion in research and development, reflecting a year-on-year increase of 1.7%. Based on the performance in the first three quarters, Johnson & Johnson has raised its full-year revenue forecast to $83.6-84.0 billion, with the revenue growth rate adjusted to 7.5%-8.0%.

In terms of business segments, pharmaceuticals revenue for the first three quarters was $41.037 billion (+4.2%), with Q3 revenue at $13.893 billion (+5.1%); medical devices revenue was $22.727 billion (+10%), with Q3 revenue at $7.458 billion (+10.0%).

Revenue from some key products:

Ustekinumab (Stelara): Revenue for the first three quarters was $8.105 billion (+10.5%), Q3 revenue was $2.864 billion (+16.9%).
Guselkumab (Tremfya): Revenue for the first three quarters was $2.237 billion (+16.8%), Q3 revenue was $8.91 billion (+22.2%).
Daratumumab (Darzalex): Revenue in the first three quarters was $7.194 billion (+22.1%), and Q3 revenue was $2.499 billion (+21.8%).
Cilta-cel (Carvykti): Revenue of $3.41 billion in the first three quarters, and $1.52 billion in Q3.
Ibrutinib (Imbruvica): Revenue for the first three quarters was $2.476 billion (-15.2%), Q3 revenue was $808 million (-11.3%).

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position;For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.

Exciting Preview

Online Live Streaming & Offline Salon

↑ Long PressScan the code, Schedule Live ↑